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Abstract
Background: Knowledge on the impact of pretreatment statin therapy on presentation of
patients with coronary artery disease (CAD) is incomplete. The aim of this study was to
investigate the impact of statin pretreatment on presentation patterns of patients with CAD.
Methods: The study included 12,989 consecutive patients with CAD who underwent coronary
angiography. The primary outcome was presentation as stable angina or acute coronary
syndrome (ACS) according to statin pretreatment.
Results: At the time of presentation, 8147 (62.7%) patients were receiving statins and 4842
(37.3%) patients were not receiving statins. Presentation pattern in patients receiving statins
vs. those not receiving statins was: stable angina in 5939 (72.9%) vs. 2102 (43.4%) patients;
odds ratio (OR) = 3.50, 95% confidence interval (CI) 3.25–3.78; p < 0.001; unstable angina
in 1435 (17.6%) vs. 1011 (20.9%) patients; OR = 0.81, 95% CI 0.74–0.89; p < 0.001; non-
-ST-segment elevation myocardial infarction (NSTEMI) in 463 (5.7%) vs. 505 (10.4%) pa-
tients; OR = 0.52, 95% CI 0.45–0.59; p < 0.001; and ST-segment elevation myocardial
infarction (STEMI) in 310 (3.8%) vs. 1224 (25.3%) patients; OR = 0.11, 95% CI 0.10–0.13;
p < 0.001. Gensini score (median [25th to 75th percentiles]) was significantly higher in patients
on statins presenting with stable angina (26.5 [13.0–59.5] vs. 21.0 [10.5–47.4]; p < 0.001) or
ACS (39.3 [17.5–77.0] vs. 37.0 [18.0–64.0]; p = 0.001). In multivariable analysis, statin
therapy was an independent correlate of reduced presentation with ACS (adjusted OR = 0.35
[0.32–0.39]; p < 0.001) or STEMI (adjusted OR = 0.18 [0.16–0.22]; p < 0.001).
Conclusions: Despite having a higher coronary atherosclerotic burden, patients with CAD on
statin therapy have reduced odds for presentation with ACS and STEMI compared to patients
not receiving statins. (Cardiol J 2013; 20, 1: 52–58)
Key words: acute coronary syndrome, angina, atherosclerosis, myocardial
infarction, statins
Introduction
Coronary artery disease (CAD) is a leading
cause of morbidity and mortality worldwide. Am-
ple evidence shows that progression of atheroscle-
rosis and, in particular, transition from stable to
unstable coronary atherosclerotic plaque(s) under-
lies clinical manifestations of CAD including pre-
sentation with acute coronary syndrome (ACS).
Earlier angiographic studies [1–3] have shown that
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acute coronary occlusions resulting in ACS occur
preferentially at the sites of non-critical coronary
narrowing. However, recent studies in more con-
temporaneous series of patients and with the use
of advanced imaging technology have shown that
majority of acute myocardial infarctions (AMI) oc-
cur at the sites of critical coronary stenoses [4, 5].
In a recent study of patients with stable and unsta-
ble CAD, we showed that severe stenoses (those
causing ≥ 75% narrowing) mediate almost all the
risk related to atherosclerotic burden for presen-
tation as unstable CAD [6]. In this study, we hy-
pothesized that, widespread use of statins and an-
tithrombotic therapy in more contemporaneous
series of patients, through their lipid-lowering,
plaque-stabilizing, anti-inflammatory and anti-
thrombotic effects may have changed the natural
course of atherosclerotic plaque reducing plaque
vulnerability to rupture allowing plaques to reach
critical degrees of lumen obstruction without clini-
cal events [6]. Although, a low incidence of cardiac
events [7–9], reduced odds of presenting with AMI
[10, 11] and reduced incidence of plaque rupture [12,
13] by statin pretreatment have been reported,
knowledge on the impact of statin therapy on pre-
sentation patterns of patients with CAD remains far
from complete. We undertook this study to inves-
tigate the impact of statin pretreatment on the pre-
sentation patterns of patients with CAD undergo-
ing percutaneous coronary intervention (PCI).
Methods
Patients
This study included a consecutive series of
12,989 patients with CAD who underwent coronary
angiography and PCI in our hospital between March
2000 and December 2009. Eligible for the study
were patients with the clinical diagnosis of stable
CAD or ACS confirmed by coronary angiography,
in whom the information of statin use before admis-
sion was available. The diagnosis of stable angina
was based on the presence of chest pain that did
not change its pattern in the preceding 2 months.
Unstable angina was diagnosed using Braunwald’s
criteria [14]. Non-ST-segment elevation myocardial
infarction (NSTEMI) was diagnosed in the presence
of chest pain highly suggestive of myocardial is-
chemia, elevated troponin level (4th generation car-
diac troponin T > 0.03 µg/L), documentation of sig-
nificant CAD (culprit lesions) in coronary angio-
graphy, but no ST-segment elevation in the
electrocardiogram. ST-segment elevation myocar-
dial infarction (STEMI) was diagnosed in the pres-
ence of chest pain lasting ≥ 20 min associated with
ST-segment elevation in the electrocardiogram
(ST-segment elevation of ≥ 0.1 mV in ≥ 2 limb
leads or ≥ 0.2 mV in ≥ 2 contiguous precordial leads
or complete left bundle branch block of new onset)
and documentation of culprit coronary lesions in
coronary angiography. All patients gave informed
consent for coronary angiography and PCI. The
study has been carried out in accordance with the
Declaration of Helsinki and has been approved by
the institutional ethics committee.
Definitions of risk factors
Data on history of disease, statin therapy be-
fore admission and cardiovascular risk factors were
collected in every patient. Hypercholesterolemia
was defined as a documented total cholesterol va-
lue ≥ 220 mg/dL or prior or ongoing treatment with
a lipid lowering agent. Arterial hypertension was
diagnosed when a patient was receiving active treat-
ment with antihypertensive drugs or if on 2 separate
occasions the systolic blood pressure was 140 mm
Hg or greater or the diastolic blood pressure 90 mm
Hg or greater. Criteria for the diagnosis of diabe-
tes were: active treatment with insulin or oral hy-
poglycemic agents on admission; documentation of
an abnormal fasting blood glucose (> 125 mg/dL);
blood glucose > 200 mg/dL at any time; or abnor-
mal glucose tolerance test based on the World
Health Organization criteria. Smokers were defined
as those currently smoking any tobacco. Body mass
index was calculated using patients’ weight and
height measured during the hospital course. The
glomerular filtration rate was estimated using the
Cockcroft-Gault formula [15].
Coronary angiography
and stent implantation
Digital angiograms were analyzed offline with
an automated edge detection system (CMS; Medis
Medical Imaging Systems, Nuenen, The Nether-
lands) in the core angiographic laboratory. CAD was
diagnosed in the presence of coronary stenoses
≥ 50% lumen obstruction in, at least, 1 of the 3 major
coronary arteries. Coronary atherosclerotic burden
was estimated using the Gensini score [16]. A cul-
prit lesion was described in the presence of an acute
occlusion, intraluminal filling defects (or thrombus),
ulcerated plaques with contrast-filled pocket pro-
truding into plaque with or without delayed contrast
wash-out, extraluminal contrast, dissection or in-
traluminal flaps. The complexity of lesions was de-
fined according to the modified American College
of Cardiology/American Heart Association grading
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system. Class B2 and C lesions were considered
complex. Left ventricular ejection fraction (LVEF)
was measured using the area-length method on left
ventricular angiograms [17].
Stent implantation and periprocedural care
were performed according to standard criteria. An-
tiplatelet therapy consisted of clopidogrel (300 mg
or 600 mg as a loading dose followed by 75 mg/day
for at least 4 weeks) and aspirin (200 mg/day ad-
ministered orally and continued indefinitely).
Outcome
The main outcome analysis was presentation
pattern according to statin therapy on admission.
Clinical presentation as stable angina, unstable an-
gina, NSTEMI or STEMI in groups with or without
statin therapy at the time of admission was analyzed.
Statistical analysis
Data are presented as median (25th to 75th per-
centiles) or counts and proportions (%). The nor-
mality of distribution of continuous data was as-
sessed using the Kolmogorov-Smirnov test. Con-
tinuous data were compared with the Kruskal-
-Wallis rank-sum test. Categorical data were com-
pared with c2 test. Multiple logistic regression
model was used to test the association between
statin therapy before admission and clinical pre-
sentation as ACS or STEMI (2 separate models).
All variables of Table 1 except for type of inter-
Table 1. Baseline data, type of intervention and therapy at discharge according to statin therapy on
admission.
Characteristic With statins (n = 8147) Without statins (n = 4842) P
Age [years] 67.4 [59.8; 74.3] 67.5 [59.2; 75.3] 0.297
Women 1761 (21.6) 1278 (24.4) < 0.001
Arterial hypertension 5945 (73.0) 3010 (62.2) < 0.001
Hypercholesterolemia 7022 (86.2) 2105 (43.5) < 0.001
Diabetes 2377 (29.2) 1252 (25.9) < 0.001
   On insulin therapy 788 (9.7) 374 (7.7) < 0.001
Body mass index [kg/m2] 27.0 [24.7; 29.7] 26.6 [24.4; 29.4] < 0.001
Current smoker 996 (12.2) 1040 (21.5) < 0.001
Prior myocardial infarction 3236 (39.7) 895 (18.5) < 0.001
Prior coronary artery bypass surgery 1594 (19.6) 362 (7.5) < 0.001
Glomerular filtration rate [mL/min] 80.8 [61.3; 102.6] 78.5 [59.0; 100.8] < 0.001
C-reactive protein [mg/L] 1.91 [0.85; 5.00] 3.54 [1.40; 10.40] < 0.001
Number of affected coronary arteries: < 0.001
1 973 (11.9) 1281 (26.5)
2 2041 (25.1) 1389 (28.7)
3 5133 (63.0) 2172 (44.8)
Multivessel disease 7174 (88.1) 3561 (73.5) < 0.001
Complex lesions 6065 (74.4) 3762 (77.7) < 0.001
Gensini score 30.0 [14.0; 65.0] 30.0 [13.5; 57.0] 0.002
Patients with stable angina 26.5 [13.0; 59.5] 21.0 [10.5; 47.4] < 0.001
Patients with ACS 39.3 [17.5; 77.0] 37.0 [18.0; 64.0] 0.001
Vessel treated: < 0.001
Left main coronary artery 407 (5.0) 174 (3.6)
Left descending coronary artery 2973 (36.5) 2114 (43.7)
Left circumflex coronary artery 2043 (25.1) 1087 (22.4)
Right coronary artery 2282 (28.0) 1355 (28.0)
Bypass graft 442 (5.4) 112 (2.3)
Left ventricular ejection fraction (%) 58.0 [49.0; 62.0] 55.0 [45.0; 62.0] < 0.001
Type of intervention: < 0.001
Coronary stenting 7247 (89.0) 4557 (94.1)
Balloon angioplasty 900 (11.0) 285 (5.9)
Data are median [25th; 75th percentiles] or number of patients (%); ACS — acute coronary syndrome
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vention were entered into the models. All analyzes
were performed using S-plus statistical package
(S-PLUS, Insightful Corp, Seattle, Washington).
A 2-tailed p < 0.05 was considered to indicate sta-
tistical significance.
Results
Baseline characteristics
Overall, there were 12,989 patients included.
At the time of admission, 8147 (62.7%) patients were
on statin therapy and 4842 (37.3%) patients were
not receiving statins. Baseline characteristics of pa-
tients are shown in Table 1. With the exception of
age, all other characteristics appear to differ signi-
ficantly in groups with or without statins at the time
of admission. In general, patients on statin therapy
appear to have a more adverse cardiovascular risk
profile, a higher atherosclerotic burden and more
extensive CAD than patients not receiving statins
at the time of admission. The predominant factor
underlying the difference in the atherosclerotic
burden (Gensini score) was the proportion of pa-
tients with a high atherosclerotic burden (those in
the 4th quartile of Gensini score) in the statin thera-
py group. On the other hand, patients receiving
statins had lower levels of C-reactive protein and
slighty but significantly higher glomerular filtration
rates and LVEF (Table 1). Coronary stents were
implanted in 11,804 (91.0%) patients and balloon
angioplasty without stent placement was performed
in 1185 (9.0%) patients.
Clinical presentation
Overall, 8041 (62.0%) patients presented with
stable angina and 4948 (38.0%) patients presented
with ACS (Table 2; Fig. 1). As seen in the Table 2,
pre-treatment with statins markedly increased the
odds for presentation with stable angina and de-
creased the odds for presentation with ACS (unsta-
ble angina, NSTEMI or STEMI). When presenta-
tion was assessed only for patients with ACS, then
pretreatment with statins significantly increased
the odds for presentation with unstable angina or
NSTEMI and decreased the odds for presentation
with STEMI (Table 2; Fig. 2).
Correlates of presentation
with ACS and STEMI
The association between statin pretreatment
and clinical presentation was adjusted for potential
confounders using the multivariable logistic regres-
sion (see Methods for variables entered into the
Table 2. Clinical presentation in groups with and without statins.
Clinical presentation With statins Without statins Odds ratio [95% CI] P
All patients (n = 12,989) N = 8147 N = 4842
   Stable angina 5939 (72.9) 2102 (43.4) 3.50 [3.25; 3.78] < 0.001
   Unstable angina 1435 (17.6) 1011 (20.9) 0.81 [0.74; 0.89] < 0.001
   NSTEMI 463 (5.7) 505 (10.4) 0.52 [0.45; 0.59] < 0.001
   STEMI 310 (3.8) 1224 (25.3) 0.11 [0.10; 0.13] < 0.001
Patients ACS (n = 4948) N = 2208 N = 2740
   Unstable angina 1435 (65.0) 1011 (36.9) 3.17 [2.82; 3.57]* < 0.001
   NSTEMI 463 (21.0) 505 (18.4) 1.17 [1.02; 1.35]* 0.025
   STEMI 310 (14.0) 1224 (44.7) 0.20 [0.17; 0.23]* < 0.001
Data are number of patients (%);*Shows the odds of presentation patterns within the group of patients with acute coronary syndrome (ACS);
CI — confidence interval; NSTEMI — non-ST-segment elevation myocardial infarction; STEMI — ST-segment elevation myocardial infarction
Figure 1. Presentation patterns according to statin thera-
py on admission; NSTEMI — non-ST-segment elevation
myocardial infarction; STEMI — ST-segment elevation
myocardial infarction.
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associates of presentation with STEMI and the
direction of associations are shown in Table 4.
Discussion
The main findings of present study can be sum-
marized as follows: (1) Statin pretreatment mark-
edly change the pattern of presentation of patients
with angiography-proven CAD. Specifically, thera-
py with statins before admission significantly in-
creased the proportion of patients presenting with
stable CAD and reduced the proportion of patients
presenting with ACS as compared with patients not
on statin therapy at the time of admission. (2) Pa-
tients on statin therapy at the time of coronary
events have a significantly higher atherosclerotic
burden (estimated by Gensini score) despite pre-
sentation with stable CAD or ACS. (3) Within the
group of patients with ACS those on statins present-
ed more often with unstable angina and NSTEMI
and less often with STEMI. Of note, either in the
whole group of patients or only in patients with ACS,
statin pretreatment markedly reduced the occur-
rence of STEMI. Considering that a substantial
number of patients with obstructive CAD are not
being treated with statins [18], current findings may
offer further evidence for the benefits of statins in
patients with CAD and draw attention for a broader
use of statins in these patients.
Anatomopathological studies have shown that
the rupture-healing cycle(s) are part of the natural
history of atherosclerotic plaques [19]. Although,
the vast majority of these cycles may remain clini-
cally silent [19], evidence available suggest that
they contribute to plaque progression leading to
progressive narrowing and tighter stenoses [20, 21]
or acute coronary events [19, 22]. The so-called
Figure 2. Presentation patterns according to statin the-
rapy on admission in patients with acute coronary syn-
drome; NSTEMI — non-ST-segment elevation myocar-
dial infarction; STEMI — ST-segment elevation myocar-
dial infarction.
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Table 3. Independent predictors of presentation with acute coronary syndromes.
Characteristic Adjusted odds ratio P
[95% confidence interval]
Statins on admission 0.35 [0.32; 0.39] < 0.001
Male sex 1.37 [1.24; 1.52] < 0.001
Arterial hypertension 0.77 [0.70; 0.84] < 0.001
Current smoking 1.59 [1.41; 1.79] < 0.001
Hypercholesterolemia 1.11 [1.01; 1.23] 0.039
Previous myocardial infarction 0.59 [0.53; 0.65] < 0.001
Previous coronary artery bypass surgery 0.65 [0.56; 0.77] < 0.001
Multivessel disease (vs. single vessel) 1.15 [1.03; 1.30] 0.012
C-reactive protein (for 5 mg/L increase) 1.09 [1.08; 1.11] < 0.001
Gensini score (for a 10-point increase) 1.06 [1.05; 1.07] < 0.001
Left ventricular ejection fraction (for a 10% decrease) 1.26 [1.21; 1.31] < 0.001
model). When applied to test the association be-
tween statin pre-treatment and presentation with
ACS vs. presentation with stable angina, statin pre-
treatment remained a significant independent cor-
relate of decreased presentation with ACS (adjust-
ed odds ratio [OR] = 0.35, 95% confidence interval
[CI] 0.32–0.39; p < 0.001). Other independent as-
sociates of presentation with ACS and the direction
of associations are shown in Table 3. When applied
to test the association between statin pre-treatment
and presentation with STEMI, again, statin pre-
treatment remained a significant correlate of de-
creased presentation as STEMI (adjusted OR = 0.18,
95% CI 0.16–0.22; p < 0.001). Other independent
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vulnerable plaques — characterized by large necro-
tic core, surrounded by a thin fibrotic cap and infil-
trated by various inflammatory cells — are prone
to rupture and coronary events [22]. Numerous
prior studies including those using up-to-date im-
aging technologies [12, 13, 23–25] have demonstrat-
ed that statins, through their lipid-lowering and
pleiotropic effects stabilize atherosclerotic plaques
and thus prevent, modify or delay acute coronary
events. As shown in the ASTEROID (A Study to
Evaluate the Effect of Rosuvastatin on Intravascu-
lar Ultrasound-Derived Coronary Atheroma Bur-
den) trial, a 53.2% reduction in the LDL-cholester-
ol by 40 mg/day rosuvastatin was associated with
a 6.7% reduction in the total plaque volume over
a 2-year follow-up [26]. Morphological studies in
transplanted hearts have also shown a marked re-
duction in the plaque inflammation by statins [27].
A slowdown of plaque progression by statins [28]
or atheromatous plaque rupture and healing with-
out significant plaque modification in patients re-
ceiving statin and antithrombotic therapies [29]
have also been reported.
These studies showed that statins may have
changed the natural course of atherosclerotic
plaques and their relationship with clinical presen-
tation and events in patients with CAD. Thus, the
widely-held concept that mild-to-moderate plaques
have e propensity to become instable and thus pose
a greater risk for coronary events than tighter
plaques seems to loose ground in the statin era.
Several recent studies have shown that high-grade
stenoses are important predictors of presentation
with STEMI [4, 5, 30] or other ACS [6]. A recent
Table 4. Independent predictors of presentation with ST-segment elevation myocardial infarction.
Characteristic Adjusted odds ratio P
[95% confidence interval]
Statins on admission 0.18 [0.16; 0.22] < 0.001
Male sex 1.38 [1.17; 1.62] < 0.001
Arterial hypertension 0.47 [0.41; 0.54] < 0.001
Diabetes 1.22 [1.04; 1.43] 0.015
Current smoking 2.04 [1.73; 2.40] < 0.001
Hypercholesterolemia 1.11 [1.01; 1.23] 0.039
Previous myocardial infarction 0.34 [0.28; 0.41] < 0.001
Previous coronary artery bypass surgery 0.41 [0.31; 0.56] < 0.001
Multivessel disease (vs. single vessel) 1.54 [1.31; 1.82] < 0.001
C-reactive protein (for 5 mg/L increase) 1.04 [1.03; 1.05] < 0.001
Glomerular filtration rate (for 10 mL/min decrease) 1.05 [1.02; 1.08] 0.003
Gensini score (for a 10-point increase) 1.09 [1.07; 1.11] < 0.001
Left ventricular ejection fraction (for a 10% decrease) 1.56 [1.47; 1.65] < 0.001
study by Zaman et al. [30] showed that most base-
line lesions showed significant luminal narrowing
when examined < 3 months before STEMI. In
a recent study, we showed that almost the entire
risk related to atherosclerotic burden for present-
ing with unstable angina was mediated by stenoses
≥ 75% of lumen obstruction [6]. A prior publication
of the Global Registry of Acute Coronary Events
(GRACE), showed that patients who were already
taking statins at the time of presentation were less
likely to have ST-segment elevation or AMI [11].
A prior case-control study of 1384 patients present-
ing with AMI or angina, showed that statin and beta-
blocker use was associated with lower odds of pre-
senting with AMI than with stable angina [10]. By
demonstrating a positive effect of statin therapy
across the whole spectrum of patients with CAD in
terms of a marked reduction of the presentation
with ACS and in particular of the presentation with
STEMI, the present study seems to corroborate
these studies in a large series of patients with an-
giography-proven CAD.
The finding that atherosclerotic burden was
higher in patients on statin therapy despite reduced
severity of clinical presentation is important for
several reasons, Firstly, this finding may imply that
statin therapy through plaque-stabilizing effects
may have reduced plaque propensity to rupture al-
lowing plaques to reach advanced stages without
complications and clinical events. Supporting these
views, a higher CAD burden at the time of presen-
tation for STEMI in patients pretreated with statins
[31] and a high coronary atherosclerotic burden in
asymptomatic patients with familial hypercholeste-
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rolemia receiving statin therapy [32] have been de-
scribed. Secondly, higher atherosclerotic burden at
the time of presentation may explain the observed
shift in the presentation patterns toward more be-
nign clinical forms for at least 2 reasons: first, cor-
onary occlusions at the site of a critical stenosis
functionally might be less important than coronary
occlusion of mild-to-moderate stenoses because the
amount of coronary flow that is interrupted might
be already small and, second, critical stenoses might
have promoted collateral development which fur-
ther attenuates the clinical presentation of acute
coronary occlusion. There are reports that statins
may enhance coronary collateral formation in pa-
tients with severe CAD [33]. Thirdly, within the
group of patients presenting with ACS, these effects
may explain the increased proportions of unstable
angina and NSTEMI, known to have a higher ath-
erosclerotic burden than patients with STEMI [34].
Finally, these findings may offer an explanation for
the observed trend of reduced incidence of STEMI
[35] potentially implicating widespread statin use
in contemporary patients.
Conclusions
In conclusion, statin pretreatment markedly
change the pattern of presentation of CAD. The
proportion of patients presenting with stable angi-
na was markedly increased and the proportions of
patients presenting with ACS and STEMI were
markedly decreased in patients receiving statins
compared to patients not receiving stations at the
time of hospital admission. Despite reduced sever-
ity of clinical presentation in patients receiving sta-
tins, these patients had a significantly higher ath-
erosclerotic burden as compared to patients not
receiving statins at the time of coronary events. The
study offers support for a broader use of statins in
patients with obstructive CAD.
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